MOTS EN ANGLAIS EN RAPPORT AVEC «DAUNORUBICIN»
daunorubicin
mechanism
action
brand
name
hydrochloride
prescribing
information
cardiotoxicity
package
insert
side
effects
doxorubicin
daunorubicin
daunomycin
chemotherapeutic
anthracycline
family
that
given
treatment
some
types
cancer
most
commonly
used
american
society
acute
lymphocytic
myelocytic
leukemias
macmillan
support
find
more
about
chemotherapy
drug
myeloid
leukaemia
cerubidine
description
user
learn
prescription
medication
uses
dosage
interactions
warnings
reviews
patient
labeling
intravenous
pictures
medical
webmd
including
safety
chemocare
trade
cerubidine®
other
names
rubidomycin
medlineplus
injection
must
hospital
facility
under
supervision
doctor
experienced
giving
cerubidin
research
cancerhelp
leukaemias
anti
tumour
antibiotic
also
called
10 LIVRES EN ANGLAIS EN RAPPORT AVEC «DAUNORUBICIN»
Découvrez l'usage de
daunorubicin dans la sélection bibliographique suivante. Des livres en rapport avec
daunorubicin et de courts extraits de ceux-ci pour replacer dans son contexte son utilisation littéraire.
1
Advances in
Daunorubicin Research and Application: 2011 ...
Advances in Daunorubicin Research and Application: 2011 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Daunorubicin in a concise format.
2
Current Medicinal Chemistry
Reduction of the Toxicity of Doxorubicin and Other Anthracyclines Cardiotoxicity
associated with anthracyclines was not detected in preclinical studies, but was
first observed during early clinical trials with daunorubicin [129] and doxorubicin
...
3
DOXORUBICIN: ANTICANCER ANTIBIOTICS
Daunorubicin, 9-deacety1-9-oxiranyl synthesis, 176 N-trifluoroacetate, 37
Daunorubicin, 3'-deamino-3',5-di-epi-3'hydroxy, 238 Daunorubicin, 3'-deamino-3'
,5'-di-epi-3',6'dihydroxy, 238 Daunorubicin, 3'-deamino-5'-epi-3'-hydroxy, 238 ...
4
Neoplastic Diseases of the Blood
There is no evidence that increasing the dose of daunorubicin by as much as one
-third [100, 112] or that double [113] or larger doses of cytarabine [114] improves
outcome. However, recent data suggest that much larger doses of daunorubicin ...
Peter H. Wiernik, John M. Goldman, Janice P. Dutcher, 2012
5
Leukemias: Principles and Practice of Therapy
studies by ECOG, the Southwestern Oncology Group (SWOG), and CALGB have
demonstrated higher CR rates when the daunorubicin dose is increased to >45
mg/m 2 in patients <60 years of age (Table 10.2). Based on these intriguing ...
Stefan Faderl, Hagop Kantarjian, 2011
6
Cancer Chemotherapy and Biotherapy: Principles and Practice
Daunorubicin (Daunomycin) and Doxorubicin The anthracycline antibiotics
doxorubicin and daunorubicin, initially discovered over 45 years ago,1,2 are
used widely in current oncologic practice; their antineoplastic spectrum of action
...
Bruce A. Chabner, Dan L. Longo, 2010
7
Apoptosis in Neurobiology
7.2.1.2 De Novo Synthesis Daunorubicin is an anthracycline antibiotic that
induces apoptosis and is widely used in cancer chemotherapy. Not surprisingly,
ceramide mimicked the effect of daunorubicin in inducing apoptosis in U937
human ...
Yusuf A. Hannun, Rose-Mary Boustany, 1998
8
Index Nominum 2000: International Drug Directory
Daunoblastin® — » Daunorubicin Daunoblastina® — » Daunorubicin
Daunomicina® — » Daunorubicin Daunomycin — ▻ Daunorubicin Daunorubicin
— » Daunorubicin Daunorubicina — ▻ Daunorubicin Daunorubicine — »
Daunorubicin ...
9
ADV IN PHARMACOLOGY &CHEMOTHERAPY
higher than the dose of doxorubicin utilized in the vitamin E studies in mice. The
in vivo evidence clearly indicates that either ICRF-159 or ICRF-187 is capable of
significantly reducing the toxic effects of a high dose of daunorubicin.
10
Razoxane and Dexrazoxane - Two Multifunctional Agents: ...
The information gained from the isolated heart experiments began to be explored
in the hamster model given high intravenous (iv) doses of daunorubicin (the
same high iv doses of doxorubicin caused lethality during injection). In these ...
Kurt Hellmann, Walter Rhomberg, 2010
10 ACTUALITÉS CONTENANT LE TERME «DAUNORUBICIN»
Découvrez de quoi on parle dans les médias nationaux et internationaux et comment le terme
daunorubicin est employé dans le contexte des actualités suivantes.
Celator® Pharmaceuticals to Host Analyst and Investor Day on July …
Celator's pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid ... «PR Newswire, juil 15»
Genetic screening reveals a link between Wnt signaling and …
Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007; 67: 5425–5433. | Article | PubMed | ISI | CAS |; Eadon ... «Nature.com, juil 15»
Five Italian Unesco sites you won't have heard of
Once the microbe was isolated it was used to produce the anti-cancer medicine, Daunorubicin. Monte San Giorgio - Lombardy. A perfectly ... «The Local.it, juil 15»
From initiation to eradication: the lifespan of an MLL-rearranged …
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International ... «Nature.com, juil 15»
Acute Myeloid Leukemia Therapeutics Market by Market Research …
... diagnosed elderly patients) is typically the combination of the two chemotherapeutic agents cytarabine and daunorubicin, both of which were ... «Medgadget.com, juil 15»
High Complete Responses Seen With CPX-351 in AML
In the comparator arm, patients received conventional 7+3 cytarabine/daunorubicin, which demonstrated a CR/CRi of 33.3%. The relative ... «Targeted Oncology, juil 15»
Celator Pharmaceuticals (CPXX) - Research Analysts' Weekly …
Celator's lead product is CPX-351, a liposomal formulation of cytarabine:daunorubicin for the treatment of acute myeloid leukemia. «Dakota Financial News, juil 15»
Intention Seekers on News: Cypress Semiconductor Corporation …
Celator's lead product is CPX-351, a liposomal formulation of cytarabine:daunorubicin for the treatment of acute myeloid leukemia. «Citizen Dispatch, juil 15»
The Leukemia & Lymphoma Society Accelerates Payment Linked to …
... of the final payment linked to the Phase 3 study of CPX-351 (cytarabine:daunorubicin) liposome injection, Celator's lead product candidate, ... «Drug Discovery & Development, juin 15»
Stocks Beats on Views- Automatic Data Processing, Inc. (NASDAQ …
... 3 study of CPX-351 (cytarabine:daunorubicin) liposome injection, Celator's lead product candidate, for the treatment of patients with high-risk ... «StreetWise Report, juin 15»
